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ABSTRACT
Introduction The utility of HbA1c (glycosylated 
hemoglobin) to estimate glycemic control in 
populations of African and other low- resource 
countries has been questioned because of high 
prevalence of other medical conditions that may affect 
its reliability. Using continuous glucose monitoring 
(CGM), we aimed to determine the comparative 
performance of HbA1c, fasting plasma glucose (FPG) 
(within 5 hours of a meal) and random non- fasting 
glucose (RPG) in assessing glycemic burden.
Research design and methods We assessed the 
performance of HbA1c, FPG and RPG in comparison 
to CGM mean glucose in 192 Ugandan participants 
with type 2 diabetes. Analysis was undertaken in all 
participants, and in subgroups with and without medical 
conditions reported to affect HbA1c reliability. We then 
assessed the performance of FPG and RPG, and optimal 
thresholds, in comparison to HbA1c in participants 
without medical conditions thought to alter HbA1c 
reliability.
Results 32.8% (63/192) of participants had medical 
conditions that may affect HbA1c reliability: anemia 
9.4% (18/192), sickle cell trait and/or hemoglobin 
C (HbC) 22.4% (43/192), or renal impairment 6.3% 
(12/192). Despite high prevalence of medical conditions 
thought to affect HbA1c reliability, HbA1c had the 
strongest correlation with CGM measured glucose in 
day- to- day living (0.88, 95% CI 0.84 to 0.91), followed 
by FPG (0.82, 95% CI 0.76 to 0.86) and RPG (0.76, 95% 
CI 0.69 to 0.81). Among participants without conditions 
thought to affect HbA1c reliability, FPG and RPG had 
a similar diagnostic performance in identifying poor 
glycemic control defined by a range of HbA1c thresholds. 
FPG of ≥7.1 mmol/L and RPG of ≥10.5 mmol/L correctly 
identified 78.2% and 78.8%, respectively, of patients 
with an HbA1c of ≥7.0%.
Conclusions HbA1c is the optimal test for monitoring 
glucose control even in low- income and middle- income 
countries where medical conditions that may alter its 
reliability are prevalent; FPG and RPG are valuable 
alternatives where HbA1c is not available.
Significance of this study
What is already known about this subject?
 ► HbA1c is the gold standard for monitoring glycemic 
control.
 ► The value of HbA1c measurement among popula-
tions living in low- resource settings has been ques-
tioned because of high prevalence of other medical 
conditions that may affect test reliability, such as 
hemoglobinopathies or anemia.
What are the new findings?
 ► HbA1c is the overall best measure of glycemic 
burden, despite high prevalence of other medical 
conditions that may affect its accuracy (eg, anemia, 
hemoglobinopathies).
 ► Fasting plasma glucose (FPG) and random non- 
fasting glucose (RPG) were strongly correlated with 
continuous glucose monitoring (CGM) glucose and 
HbA1c, and had reasonable sensitivity and specifici-
ty to detect poor glycemic control.
 ► The difference in performance between these tests 
is modest.
How might these results change the focus of 
research or clinical practice?
 ► HbA1c is the optimal laboratory method for as-
sessing glycemic control, even in populations with 
high prevalence of conditions reported to affect test 
reliability.
 ► FPG and RPG measurements correlate strongly with 
both CGM and HbA1c, perform reasonably well in 
identifying poor glycemic control and can therefore 
be used when HbA1c is unavailable.
2 BMJ Open Diab Res Care 2021;9:e002350. doi:10.1136/bmjdrc-2021-002350
Clinical care/Education/Nutrition
INTRODUCTION
Diabetes is a global problem disproportionately 
affecting low- income and middle- income countries 
(LMICs), with 80% of the global 463 million people 
with diabetes living in LMICs.1 Unlike high- income 
countries, diabetes healthcare in LMICs is under-
funded1 and lacks quality, pragmatic and contextual-
ized guidelines.2 As such, LMICs are heavily impacted 
by high rates of poorly controlled glucose levels,3–5 and 
subsequently, high rates of diabetes- related complica-
tions and poor quality of life among people living with 
diabetes.
Monitoring glycemic control is essential to allow 
appropriate titration of medication and improve 
outcomes among patients with diabetes, but regular 
monitoring can be challenging in LMICs. In high- 
income countries, HbA1c (glycosylated hemoglobin) is 
the recommended measure used for assessing glucose 
control and titrating medications, often supported by 
home glucose capillary or interstitial glucose moni-
toring.6 7 However, financial constraints mean that the 
monitoring of diabetes and decisions to intensify treat-
ment in much of the low- income regions are predom-
inantly based on testing of a single glucose measure.8 
This is because HbA1c testing is not routinely available 
in most centers,8 and HbA1c is often too expensive for 
the majority of patients.9 Even where testing is available, 
there has been substantial concern that HbA1c measure-
ment may be unreliable in LMIC populations,10–12 due 
to high prevalence of hemoglobinopathies such as 
sickle cell and thalassemia, and other medical condi-
tions that might affect test reliability including anemia 
and malaria.13 Home glucose monitoring is not well 
funded by healthcare systems in LMICs and is beyond 
the financial means and literacy skills of a large propor-
tion of those who have diabetes.8 14
International organisations recommend the use of 
plasma glucose for monitoring glycemic control in 
developing countries where HbA1c services are not 
readily available.15 However, assessment of glycemic 
control in such settings is normally after long walks 
by the patients to attend a centralized clinic every 
2–3 months, coupled with prolonged fasting and long 
waiting times.16 As such, many clinicians rely on a 
random glucose without the requirement to fast to assess 
glycemia.16 While these tests have been compared with 
HbA1c in the LMIC setting,17 18 given the limitations 
of HbA1c itself in these populations, its performance 
as a measure of average glucose is unclear. Continuous 
glucose monitoring (CGM) offers the opportunity of 
measuring glucose in day- to- day living over a period of 
days to weeks and is widely used in high- income coun-
tries and some LMICs.
In the OPTIMAL study, we aimed to compare, in an 
African population with type 2 diabetes, the accuracy 
of fasting plasma glucose (FPG), random non- fasting 
plasma glucose (RPG), and HbA1c in comparison to 
CGM as an independent measure of glycemic control, 
and assess the impact of other medical conditions that 
may affect HbA1c reliability to monitor glycemia in 
people with established diabetes.
METHODS
Study population
Participants were recruited from diabetes clinics in 
Masaka Regional Referral Hospital (rural, public) 
and St. Francis Hospital Nsambya (urban, private not- 
for- profit) in Uganda and met the following inclusion 
criteria: a clinical diagnosis of type 2 diabetes, diagnosed 
at the age of 18 years and above, more than 12 months’ 
diabetes duration, no initial insulin requirement for at 
least 1 year since the time of diagnosis, no change in 
glucose- lowering therapy 3 months prior, and able to 
give informed consent. Participants who were preg-
nant or judged by their clinician to need an immediate 
change in glucose- lowering medication were excluded 
from recruitment.
Study visits
Participants were scheduled for three visits. The overview 
of the study design is presented in online supplemental 
figure S1.
At the baseline visit, participants came to the clinic in a 
non- fasted state. Following assessment of clinical features 
and demographics, non- fasting (within 5 hours of a meal) 
random blood sample was collected for measurement of 
RPG, HbA1c, full blood count, lipid profile, renal func-
tion and assessment of hemoglobin variants. CGM was 
carried out using the Freestyle Libre Pro Flash Glucose 
Monitoring System (Abbott Laboratories, Illinois, USA), 
a professional CGM device which records interstitial 
glucose every 15 min for up to 2 weeks. Freestyle Libre 
Pro is blinded, meaning data could not be viewed by the 
wearer.
All participants returned in a fasted state (at least 8 
hours) in the second week of CGM between days 7 and 10 
from the baseline visit, and for their final visit, between 
days 12 and 14 from the baseline visit, in a non- fasted 
state (within 5 hours of a meal). At both of these visits, 
CGM data were downloaded and a venous blood sample 
was collected for measurement of HbA1c and RPG (visits 
1 and 3) and FPG (visit 2). The study was carried out in 
accordance with the 2008 revised principles of the Decla-
ration of Helsinki and all participants provided informed 
consent before study activities.
Patient and public involvement (PPI)
Patients were involved in prioritization of the research 
question. Patients were not involved in the design and 
conduct of the study. However, they were central to 
dissemination of the results by choosing to have some 
of the results sent to their respective clinicians, and will 
continue to be involved in ongoing study dissemination.
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Laboratory procedures
Blood samples for glucose measurement were collected 
in a vacutainer with sodium fluoride (NaF), centrifuged 
and separated into two cryovials (aliquots) immediately 
and kept in an icebox at 4°C–8°C before being trans-
ported to the central laboratory for immediate testing 
(within 8 hours of collection). Whole blood samples for 
full blood count and HbA1c were collected in vacutainers 
containing EDTA. All analytical measurements were 
performed at the Central Biochemistry and Clinical 
Diagnostic Laboratory Services (CDLS) laboratory at the 
MRC/UVRI & LSHTM Research Unit Entebbe Uganda. 
Laboratory analyses were performed on a Roche Cobas 
6000 analyzer (Hitachi High Technologies, Tokyo, 
Japan). Plasma glucose was measured by the glucokinase 
method. HbA1c was also measured on Cobas 6000 by the 
immunoassay technique, calibrated to the International 
Federation of Clinical Chemistry. Hemoglobinopathies 
(sickle cell trait and hemoglobin C (HbC)) were assessed 
by Hb electrophoresis.
CGM measures
Raw glucose readings were downloaded from the Libre-
view software and CGM summary variables (including 
mean CGM glucose) were calculated using R V.3.6.1. 
Sensor data were considered for analysis if the total dura-
tion of CGM wear was at least 5 days.
For CGM validation, we matched plasma FPG at visit 2 
with a nearest CGM glucose value within 15 min. We then 
determined the relationship between the plasma glucose 
and the CGM glucose value using Bland- Altman anal-
ysis to assess the degree of bias and levels of agreement 
between the sensor and plasma glucose.
Statistical analysis
Data were analyzed using Stata V.16.1 (StataCorp LLC, 
USA).
Comparison of glucose and HbA1c measures with CGM measured 
glucose in daily living
We assessed the strength of the relationship between 
CGM assessed mean glucose over 2 weeks and each of 
FPG, RPG and HbA1c using Pearson’s correlation coeffi-
cients and linear regression. Analysis was based on RPG 
and HbA1c tests performed on the last visit (visit 3), 
unless not available, in which case values from visit 1 were 
used instead (n=9). To assess the impact of other medical 
conditions (anemia, hemoglobinopathies, and renal 
impairment) on HbA1c reliability, we subdivided the 
cohort into those without medical conditions that may 
alter HbA1c reliability and those with medical conditions 
that may alter HbA1c reliability. HbA1c performance 
in comparison to CGM was assessed in all participants 
regardless of comorbidities, and by presence or absence 
of medical conditions thought to affect test perfor-
mance (see below). Equivalent thresholds for predicting 
suboptimal glycemic control (defined as CGM glucose 
values ≥8 and ≥10 mmol/L) were derived from linear 
regression equations. We compared the performance of 
RPG and FPG and HbA1c to identify participants with 
CGM glucose values ≥8 and ≥10 mmol/L using receiver 
operating characteristic curve analysis, and assessed the 
sensitivity, specificity and positive/negative predictive 
values of these tests using the equivalent cut- offs derived 
from linear regression equations.
Comparison of FPG and RPG measurement with HbA1c
As HbA1c is the measure which has been robustly vali-
dated against clinical outcomes, we performed addi-
tional analysis, where we assessed the strength of the 
relationship between HbA1c and each of the FPG and 
RPG tests in the absence of medical conditions that 
might affect HbA1c reliability. Participants were consid-
ered to have no other medical conditions that may affect 
HbA1c reliability if they met the following characteris-
tics: no hemoglobinopathies (sickle cell trait and HbC), 
absence of anemia (Hb in women ≥120 g/L, men ≥130 
g/L),19 and no renal impairment (estimated glomerular 
filtration rate (eGFR) ≥60 mL/min/1.73 m2). In partic-
ipants without these medical conditions, we determined 
diagnostic performance of the glucose tests for subop-
timal glucose control defined by HbA1c at the following 
thresholds: HbA1c ≥48 mmol/mol (6.5%), ≥53 mmol/
mol (7.0 %), 58 mmol/mol (7.5%), 64 mmol/mol 
(8.0%), 69 mmol/mol (8.5%) and 75 mmol/mol (9.0%). 
Equivalent thresholds of FPG and random glucose for 




A total of 213 adults were enrolled in the study. Of these 
participants, 9.86% (21/213) were excluded for insuffi-
cient data. Characteristics of excluded participants were 
broadly similar to those included in analysis, as shown 
in online supplemental table 1. Out of 213 participants, 
192 had sufficient data for inclusion in the final analysis 
(see flow chart: online supplemental figure S2). The 
median CGM duration was 14 (IQR 13–14) days. Partic-
ipant characteristics are presented in table 1. Average 
glycemic control was poor with a median (IQR) HbA1c 
of 67 (52.0–90.0) mmol/mol (8.3% (6.9–10)). The other 
medical conditions that may affect HbA1c reliability 
were common, occurring in 32.8% (63/192) of partic-
ipants, of whom 9.4% (18/192) had anemia, 22.4% 
(43/192) had hemoglobinopathies (sickle cell trait 
(n=43) and/or hemoglobin AC (HbAC) (n=1)), and 
6.3% (11/190) had renal impairment (eGFR <60 mL/
min/1.73 m2). Characteristics according to absence or 
presence of medical conditions that may affect HbA1c 
reliability are shown in online supplemental table 2. 
FPG and CGM glucose are highly correlated
FPG and CGM glucose (closest value, within 15 min) were 
highly correlated (Pearson’s r=0.97, 95% CI 0.96 to 0.98). 
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CGM values showed a modest bias toward lower glucose 
than FPG, with CGM values mean 1.3 (95% CI 1.1 to 1.5) 
mmol/L lower—this was consistent across the range of 
glycemic control (online supplemental figure S3).
HbA1c has the strongest relationship with CGM glucose in an 
African population, even in participants with comorbidities 
thought to alter HbA1c reliability
The relationship between HbA1c, FPG and RPG tests 
and average CGM glucose is shown in figure 1. There 
was a strong correlation between all the three tests and 
mean CGM glucose. HbA1c had the strongest correla-
tion (0.88; 95% CI 0.84 to 0.91), followed by FPG (0.82; 
95% CI 0.76 to 0.86) and RPG (0.76; 95% CI 0.69 to 
0.81). The derived linear equations for estimating mean 
glucose from HbA1c, FPG and RPG among patients with 
diabetes are shown in online supplemental table 3. The 
diagnostic performances of HbA1c, FPG and RPG tests 
for diagnosing suboptimal glucose control (defined by 
illustrative mean CGM thresholds of 8 and 10 mmol/L) 
are shown in table 2. There was a very modest loss of diag-
nostic performance using FPG compared with HbA1c, at 
equivalent thresholds. HbA1c was the most sensitive and 
specific test followed by FPG.
HbA1c maintained the strongest relationship with 
CGM glucose even in those with other medical conditions 
that might affect HbA1c reliability (figure 1). In those 
with and without conditions that might affect HbA1c reli-
ability, the relationship between CGM glucose and HbA1c 
was similar, with no difference in correlation (0.85; 
95% CI 0.76 to 0.91) versus (0.89; 95% CI 0.85 to 0.92) 
(figure 1) and the difference in linear regression slopes 
was modest (mean CGM glucose=0.14*HbA1c–0.02 and 
0.16*HbA1c–1.07 with and without conditions that may 
affect HbA1c reliability, respectively) (online supple-
mental table 3). This was also similar when examining 
only those with hemoglobinopathy (r=0.90, 95% CI 0.82 
to 0.94, n=42, supplementary figure S4).
FPG and RPG have broadly similar diagnostic performance in 
identifying patients with poor glycemia control
Among participants without conditions thought to 
alter HbA1c reliability (including hemoglobinopathies, 
anemia and renal impairment), RPG and FPG had similar 
correlation with HbA1c (0.74; 95% CI 0.65 to 0.80) and 
(0.78; 95% CI 0.71 to 0.84), respectively (figure 2). The 
equivalent thresholds and diagnostic performances 
of FPG and RPG for predicting HbA1c defined subop-
timal glucose control (at different HbA1c thresholds), 
restricted to those without conditions thought to alter 
HbA1c reliability, are shown in table 3. FPG and RPG had 
very similar performance in identifying those with subop-
timal glycemic control (table 3). For the widely used 
HbA1c target of 7.0%, the AUC ROC for these tests was 
similar (FPG 0.76, RPG 0.77). At their respective optimal 
thresholds (FPG ≥7.1 mmol/L and RPG ≥10.5 mmol/L), 
the tests had a similar sensitivity (FPG −81.0, 95% CI 71.9 
to 88.2 vs RPG −81.6, 95% CI 72.7 to 88.5) and specificity 
(FPG −71.4, 95% CI 55.4 to 84.3 vs RPG −72.1, 95% CI 
56.3 to 84.7) for identifying suboptimal glycemic control. 
The linear equations for estimating HbA1c from FPG and 
RPG among patients with diabetes were HbA1c (mmol/
mol)=5.40*FPG+21.3 and HbA1c=3.07*RPG +28.58, 
respectively, for patients without comorbidities thought 
to alter HbA1c (online supplemental table 4).
DISCUSSION
The international guidelines recommend HbA1c for 
monitoring glycemic control and blood glucose test 
where HbA1c is unavailable. Despite this guidance, 
there remains concerns about the accuracy of HbA1c in 
Table 1 Participant characteristics (N=192)
Median (IQR) for 
continuous variables, 
% (n) for proportions
Clinical
  Female, n (%) 58.3 (112/192)
  Age, years 56 (50–63)
  Duration of diabetes, years 6 (3–10)
  BMI, kg/m2 26.8 (24.0–30.5)
Current management, n (%)
  Metformin only 15.6 (30/192)
  SU (±metformin)* 57.3 (110/192)
  Insulin (±other diabetes drug)† 26.0 (50/192)
  Diet‡ 1.0 (2/192)
Glycemia
  CGM glucose, mmol/L 8.6 (6.8–12.3)
  HbA1c, % 8.3 (6.9–10.0)
  HbA1c, mmol/mol 67 (52.0–90.0)
  FPG, mmol/L 8.2 (6.1–11.4)
  RPG, mmol/L 13.5 (8.8–17.2)
Other laboratory
  Hb (g/L) 14.2 (13.2–15.0)
  Anemia§ 9.4% (18/192)
  Hemoglobinopathies, n (%)¶ 22.4% (43/192)
  eGFR 111.5 (92.3–121.0)
  Renal impairment, n (%) 6.3% (12/192)
*Sulfonylureas with or without metformin.
†Insulin with or without any oral therapy.
‡Two participants were on non- pharmacological management 
(diet) only.  
§ Anemia was defined as a Hb of <120 g/L in women and <130 
g/L in men.
¶Hemoglobinopathies was defined as the presence of sickle cell 
trait (HbAS) or HbAC.
BMI, body mass index; CGM, continuous glucose monitoring; 
eGFR, estimated glomerular filtration rate; FPG, fasting plasma 
glucose; Hb, hemoglobin; HbAC, hemoglobin AC; HbA1c, 
glycosylated hemoglobin; RPG, random non- fasting plasma 
glucose.
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populations with high frequency of other medical condi-
tions that may alter its reliability. In this study, we used 
CGM to compare the accuracy of HbA1c, FPG and RPG 
tests in assessing glycemic control among patients with 
diabetes under conditions of everyday life in low- resource 
settings. The prevalence of other medical conditions that 
may alter HbA1c reliability was remarkably high. However, 
we found that HbA1c remained the most accurate test 
of average glucose control, despite the high prevalence 
of hemoglobinopathies, anemia and renal impairment. 
Similarly, FPG and RPG demonstrated reasonable accu-
racy as measures of average glycemic control, providing 
confidence that glucose tests provide a good measure of 
glycemia where HbA1c is not available. Furthermore, the 
Figure 1 Comparison of (A) HbA1c (glycosylated hemoglobin) of the overall sample population and (B) HbA1c without (1; 
black circles) and with (2; gray circles) conditions thought to alter HbA1c reliability with mean continuous glucose monitoring 
(CGM) glucose. Comparison of (C) fasting plasma glucose (FPG) and (D) random non- fasting plasma glucose (RPG) with 
mean CGM glucose. Solid straight line denotes the line of best fit and the dashed lines represent the 95% CI. The Pearson’s 
correlation coefficient (r) and 95% CIs are shown for each graph. Conditions thought to alter HbA1c reliability include 
hemoglobinopathies including sickle cell trait and hemoglobin AC (HbAC), anemia, and renal impairment.
Table 2 Ability of HbA1c, FPG and RPG to define suboptimal glucose control using CGM thresholds <8 and <10 mmol/L
CGM 











































































The units used are as follows: HbA1c—mmol/mol and mmol/L for fasting and random non- fasting glucose.
AUROC, area under receiver operating characteristic curve; CGM, continuous glucose monitoring; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; 
NPV, negative predictive value; PPV, positive predictive value; RPG, random non- fasting plasma glucose.
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very modest loss of diagnostic test performance using 
RPG provides some reassurance for use of this test in situ-
ations where a RPG is the only or most practical measure 
available.
In the current study, we have compared FPG, RPG and 
HbA1c in the same study and more importantly against 
an independent measure of day- to- day glycemic burden. 
CGM was used as an independent marker of glycemic 
Figure 2 (A, B) Comparison of fasting plasma glucose (FPG) and random non- fasting plasma glucose (RPG) with HbA1c 
(glycosylated hemoglobin) in participants without conditions thought to alter HbA1c reliability. Solid straight line denotes the 
line of best fit and the dashed lines represent the 95% CI. The Pearson’s correlation coefficient (r) and 95% CIs are shown for 
each graph. Conditions thought to alter HbA1c reliability include hemoglobinopathies including sickle cell trait and hemoglobin 
AC (HbAC), anemia, and renal impairment.
Table 3 Ability of FPG and RPG to predict suboptimal glucose control among patients with type 2 diabetes without medical 
conditions thought to alter HbA1c reliability using different HbA1c thresholds
HbA1c 

































































































































































AUROC, sensitivity, specificity, % correctly classified, PPV and NPV are given for the respective optimal thresholds of the test. This was restricted to HbA1c where there were no 
conditions thought to alter HbA1c reliability like anemia, sickle cell traits, and renal impairment.
The units used are mmol/L for fasting and random non- fasting glucose.
AUROC, area under receiver operating characteristic curve; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; NPV, negative predictive value; PPV, positive predictive 
value; RPG, random non- fasting plasma glucose.
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burden to allow assessment of the relative performance 
of HbA1c, FPG and RPG in assessing glycemic burden. 
This is a major strength of our analysis in contrast to 
previous studies which have compared between measures 
such as HbA1c and FPG, with no independent compar-
ison. Further, we assessed performance of HbA1c in the 
presence of other medical conditions that may alter its 
effect. This gave us the opportunity to assess the overall 
impact on HbA1c reliability.
However, the present study has some limitations that 
should be taken into consideration. First, although CGM 
was the best available option for direct measurement of 
glucose in day- to- day living and allowed us to compare 
the relative performance of HbA1c and glucose tests, 
it should be noted that glycemia was measured using a 
CGM sensor over median 14 (IQR 13–14) days and yet 
HbA1c estimates glycemia over a longer duration.20 
Second, we used HbA1c immunoassay, one of the most 
widely used HbA1c assays, particularly in low- resource 
settings. However, our results for the performance might 
not apply to other HbA1c assay types, which are known 
to have different susceptibility to the effects of hemo-
globinopathies.21 Furthermore, although we screened 
for a number of potential comorbidities thought to 
alter HbA1c, with the available sample size and very 
modest subgroup numbers, we were unable to do further 
subgroup analyses to assess the impact of other individual 
underlying non- glycemic conditions.22 In addition, the 
impact of glucose-6- phosphate dehydrogenase variants, 
another common condition that may affect HbA1c 
results reliability, was not assessed.23
Our results showing a strong relationship between 
HbA1c and mean glucose from CGM are consistent with 
studies that have compared these two measures in high- 
income settings. The Diabetes Control and Complica-
tions Trial (DCCT) of participants in the USA with type 1 
diabetes showed a strong relationship between the mean 
plasma glucose and HbA1c with a Pearson correlation (r) 
of 0.82.24 Similarly, results from the ADAG (A1c Derived 
Average Glucose) study, which included 507 partici-
pants with and without diabetes predominantly from the 
USA and Europe, and excluded participants with other 
medical conditions thought to alter HbA1c reliability, 
showed HbA1c and mean glucose were closely correlated 
(r=0.89, p<0.0001).25 Our similar results (r=0.88) in an 
African population, and without exclusion of partici-
pants with analytical concerns for HbA1c measurement, 
is reassuring for the use of HbA1c testing in this region.
Our results are broadly consistent with previous 
studies that have reported the relationship between 
glucose tests and HbA1c. El- Kebbi et al showed, in 1827 
predominantly African–American living in the USA, 
that RPG collected 1–4 hour post meal was correlated 
strongly with HbA1c, although in this predominantly 
insulin- treated population, the correlation (r=0.63) was 
lower than observed in our study (0.74).26 In a study 
that compared both FPG and RPG to HbA1c among 
1000 patients with diabetes living in India, FPG showed 
a better correlation with HbA1c than RPG (0.739 vs 
0.601).27 In contrast, in studies where a fixed post meal 
time point was used, RPG was a slightly better correlate 
of HbA1c than FPG.18 Unfortunately, studies comparing 
performances of glucose tests against HbA1c in Africa 
are very few, with small sample sizes, and in these studies, 
the impact of common medical conditions that may alter 
HbA1c reliability was not assessed.17 28
Our data suggest that there is a high prevalence of other 
medical conditions that may alter HbA1c reliability justi-
fying the questioning of HbA1c utility. However, even with 
these comorbidities, HbA1c, when measured with an immu-
noassay method, correlated strongly with mean glucose, 
outperforming glucose measures, and only displayed a 
modest improvement when patients with comorbidities were 
excluded. This suggests that HbA1c remains the optimal 
laboratory method of monitoring glucose burden even 
where prevalence of conditions that may affect its reliability is 
high. The strong correlation of HbA1c with glucose despite 
the prevalence of other medical conditions that may alter 
HbA1c reliability deserves further exploration. However, 
there are some reasons why the impact of these conditions 
on HbA1c reliability may be modest in this setting. First, 
in line with the National Glycohemoglobin Standardiza-
tion Program (NGSP) recommendation, modern HbA1c 
immunoassays are not directly affected by the presence of 
hemoglobin variants like HbAS.21 Second, while comor-
bidities that affect red cell life will alter the accuracy of any 
HbA1c method, the predominant hemoglobinopathy in our 
study population was HbAS (sickle cell) trait, and previous 
research has been conflicting as to whether this meaningfully 
alters red cell lifespan.29
While our results support the use of HbA1c (where 
available) rather than glucose measures in LMIC 
populations, the small subgroup numbers in our 
study limited the power to definitively determine 
the impact of some of these comorbidities on HbA1c 
performance. To accurately determine the impact 
of individual comorbidities, larger multinational 
studies involving other regions in Africa and LMICs 
with enrichment for these comorbidities would be 
needed. Furthermore, while our data show that 
HbA1c (measured using an immunoassay method) 
has the closest relationship with average glucose, even 
with comorbidities, it is possible that the overall rela-
tionship between glucose and HbA1c is different in 
this population, therefore the thresholds used inter-
nationally are not appropriate, and bespoke HbA1c 
thresholds are needed for different populations. This 
further underscores the need for much larger studies, 
ideally incorporating risk of microvascular complica-
tions, to determine whether the HbA1c targets used 
internationally are appropriate for LMIC populations.
In conclusion, our results suggest that HbA1c is the 
optimal test for monitoring glucose control even in 
LMICs where medical conditions that may alter its 
reliability are prevalent; FPG and RPG are valuable 
alternatives where HbA1c is not available.
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